Charlton, Michael R. and Alam, Altaf and Shukla, Akash and Dashtseren, Bekhbold and Lesmana, Cosmas Rinaldi Adithya and Duger, Davadoorj and Payawal, Diana Alcantara and Duy Cuong, Do and Jargalsaikhan, Ganbolor and Cua, Ian Homer Yee and Sollano, Jose Decena and Singh, Karam Romeo and Madan, Kaushal and Win, Khin Maung and Kyi, Khin Pyone and Tun, Kyaw Soe and Salih, Mohd. and Rastogi, Mukul and Saraf, Neeraj and Thuy, Pham Thi Thu and Hien, Pham Tran Dieu and Gani, Rino Alvani and Mohamed, Rosmawati and Tanwandee, Tawesak and Piratvisuth, Teerha and Sukeepaisarnjaroen, Wattana and Naing, Win and Hashmi, Zahid Yasin (2020) An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. Journal of Gastroenterology, 55 (9). pp. 811-823. ISSN 09441174, DOI https://doi.org/10.1007/s00535-020-01698-4.
Full text not available from this repository.Abstract
Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from Asia convened, reviewed the literature, and developed the current expert opinion-based review article for the use of TAF in the resource-constrained settings in Asia. This article provides a comprehensive review of two large, phase 3, double-blind, randomized controlled trials of TAF versus TDF in HBeAg-negative (study 0108) and HBeAg-positive (study 0110) chronic HBV patients (> 70% Asians). These studies revealed as follows: (1) non-inferiority for the proportion of patients who had HBV DNA < 29 IU/mL; (2) significantly high rate of normalization of alanine aminotransferase levels; (3) no incidence of resistance; and (4) significantly better bone and renal safety, with TAF vs. TDF up to 144 weeks. Considering the benefits of TAF, the expert panel proposed recommendations for optimizing the use of TAF in Asia, along with guidance on specific patient groups at risk of renal or bone disease suitable for TAF therapy. The guidance provided in this article may help clinicians optimize the use of TAF in Asia.
| Item Type: | Article |
|---|---|
| Funders: | Mylan Pharmaceuticals Ltd. |
| Uncontrolled Keywords: | Hepatitis B virus; Nucleoside analogs; Tenofovir alafenamide; Asia |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
| Divisions: | Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 29 Oct 2024 08:12 |
| Last Modified: | 29 Oct 2024 08:12 |
| URI: | http://eprints.um.edu.my/id/eprint/36549 |
Actions (login required)
 |
View Item |
